Julio Delgado

46PUBLICATIONS
334CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Science, technology and engineering curriculum and pedagogyHaematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (46)

|Sep 30, 2026
Immunotherapy refractoriness and early post-alloHCT relapse define ultra-high-risk B-ALL after CD19 CAR T-cell therapy.

|Jul 22, 2026
CD70 Overexpression at Diagnosis Predicts Relapse and supports dual CD19-CD70 CAR-T Therapy in Follicular Lymphoma.

|Jun 12, 2026
Infections in Patients With Cytokine Release Syndrome/Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell Therapy.

|Jun 08, 2026
Varnimcabtagene autoleucel (ARI-0001) in relapsed or refractory mantle cell lymphoma.

|Mar 09, 2026
The European CAR-T map-Current status and future directions to improve access to CAR T-cell therapy for hematologic malignancies.

Elise R A Pennings, Frederick W Thielen, Florence Broussais

|Oct 22, 2025
CD19 CAR T-Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic Leukaemia.

Ofrat Beyar-Katz, Ohad Benjamini, Julio Delgado

Pageof 8

Frequent Collaborators

13 joint publications

Valentín Ortiz-Maldonado

12 joint publications

Elias Campo

9 joint publications

Pablo Mozas

9 joint publications

Ferran Nadeu